📣 VC round data is live. Check it out!

Castle Biosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Castle Biosciences and similar public comparables like Lumibird, Assure Tech, Integral Diagnostics, Jiangsu Bioperfectus and more.

Castle Biosciences Overview

About Castle Biosciences

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.


Founded

2007

HQ

United States

Employees

761

Financials (LTM)

Revenue: $347M
EBITDA: $28M

EV

$399M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Castle Biosciences Financials

Castle Biosciences reported last 12-month revenue of $347M and EBITDA of $28M.

In the same LTM period, Castle Biosciences generated $264M in gross profit, $28M in EBITDA, and had net loss of ($32M).

Revenue (LTM)


Castle Biosciences P&L

In the most recent fiscal year, Castle Biosciences reported revenue of $344M and EBITDA of $43M.

Castle Biosciences is unprofitable as of last fiscal year, with gross margin of 79%, EBITDA margin of 13%, and net margin of (7%).

See analyst estimates for Castle Biosciences
LTMLast FY202320242025202620272028
Revenue$347M$344M$220M$332M$344M
Gross Profit$264M$273M$175M$272M$273M
Gross Margin76%79%80%82%79%
EBITDA$28M$43M($45M)$38M$11M
EBITDA Margin8%13%(20%)11%3%
EBIT Margin(14%)(12%)(31%)3%(12%)
Net Profit($32M)($24M)($57M)$18M($24M)
Net Margin(9%)(7%)(26%)5%(7%)

Financial data powered by Morningstar, Inc.

Castle Biosciences Stock Performance

Castle Biosciences has current market cap of $624M, and enterprise value of $399M.

Market Cap Evolution


Castle Biosciences' stock price is $20.56.

Castle Biosciences share price decreased by 16.0% in the last 30 days, and increased by 28.7% in the last year.

Castle Biosciences has an EPS (earnings per share) of $-0.80.

See more trading valuation data for Castle Biosciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$399M$624M2.6%-16.0%-30.5%28.7%$-0.80

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Castle Biosciences Valuation Multiples

Castle Biosciences trades at 1.1x EV/Revenue multiple, and 14.4x EV/EBITDA.

See NTM and 2027E valuation multiples for Castle Biosciences

EV / Revenue (LTM)


Castle Biosciences Financial Valuation Multiples

As of May 22, 2026, Castle Biosciences has market cap of $624M and EV of $399M.

Castle Biosciences has a P/E ratio of (19.5x).

LTMLast FY202320242025202620272028
EV/Revenue1.1x1.2x1.8x1.2x1.2x
EV/EBITDA14.4x9.3x(8.9x)10.5x35.1x
EV/EBIT(8.3x)(9.3x)(5.9x)46.0x(9.3x)
EV/Gross Profit1.5x1.5x2.3x1.5x1.5x
P/E(19.5x)(25.8x)(10.9x)34.2x(25.8x)
EV/FCF61.9x14.1x(20.7x)10.9x14.1x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Castle Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Castle Biosciences Margins & Growth Rates

Castle Biosciences grew revenue by 2% but EBITDA decreased by 92% in the last fiscal year.

In the most recent fiscal year, Castle Biosciences reported gross margin of 79%, EBITDA margin of 13%, and net margin of (7%).

See estimated margins and future growth rates for Castle Biosciences

Castle Biosciences Margins

Last FY202420252026202720282029
Gross Margin79%82%79%75%
EBITDA Margin13%11%3%1%
EBIT Margin(12%)3%(12%)(16%)
Net Margin(7%)5%(7%)(13%)
FCF Margin8%11%8%(8%)

Castle Biosciences Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth2%51%4%2%
Gross Profit Growth(4%)56%0%(4%)
EBITDA Growth(92%)(185%)(70%)(69%)
EBIT Growth30%(113%)(594%)30%
Net Profit Growth83%(132%)(232%)83%
FCF Growth(198%)(290%)(22%)(198%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Castle Biosciences Operational KPIs

Castle Biosciences' revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.4M for the same period.

Castle Biosciences' Rule of 40 is 3% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Castle Biosciences' Rule of X is 7% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Castle Biosciences
LTMLast FY202320242025202620272028
Rule of 4014%3%———
Bessemer Rule of X23%7%———
Revenue per Employee—$0.5M———
Opex per Employee—$0.4M———
S&M Expenses to Revenue—40%52%37%40%
G&A Expenses to Revenue—26%30%23%26%
R&D Expenses to Revenue16%15%24%16%15%
Opex to Revenue—92%110%79%92%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Castle Biosciences Competitors

Castle Biosciences competitors include Lumibird, Assure Tech, Integral Diagnostics, Jiangsu Bioperfectus, RaySearch Labs, Abclon, Genfit, Fulgent Genetics, Diagnósticos da América and Mirxes Holding.

Most Castle Biosciences public comparables operate across Diagnostics & Genomics, Medical Imaging & Diagnostics, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Lumibird2.7x2.6x13.6x12.7x
Assure Tech6.2x—22.7x—
Integral Diagnostics2.1x1.7x12.1x8.3x
Jiangsu Bioperfectus10.9x—112.2x—
RaySearch Labs4.8x4.8x11.1x10.8x
Abclon153.5x—(44.3x)—
Genfit6.8x6.7x(15.9x)(27.7x)
Fulgent Genetics0.7x0.7x(22.7x)(8.3x)

This data is available for Pro users. Sign up to see all Castle Biosciences competitors and their valuation data.

Start Free Trial

Castle Biosciences Funding History

Before going public, Castle Biosciences raised $44M in total equity funding, across 6 rounds.


Castle Biosciences Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Apr-19Series ABrightEdge Fund$12M—Castle Biosciences, founded in 2008 and based in Friendswood, Texas, develops and commercializes innovative skin cancer diagnostics, including the DecisionDx-Melanoma assay, a gene expression profile test to identify high-risk stage I and II cutaneous melanoma patients. In April 2019, BrightEdge, the American Cancer Society's philanthropic impact fund, participated in an approximately $12 million (or $11.6 million) convertible note financing for Castle Biosciences, marking BrightEdge's first investment. BrightEdge contributed $3 million to the round. Castle Biosciences plans to use the proceeds to expand patient access to its diagnostic tests, grow its sales force, and build out its pipeline of skin-cancer diagnostic and prognostic tests.
Jun-18Series ABioBrit; Industry Ventures; MGC Venture Partners$5M——
Jul-15Series FGore Range Capital; HealthQuest Capital; Industry Ventures$12M—Castle Biosciences is a provider of molecular diagnostics designed to improve cancer treatment decisions. The company develops gene tests that go beyond traditional staging methods to identify metastatic risk and help determine optimal treatment approaches for patients diagnosed with uveal melanoma, cutaneous melanoma, esophageal cancer, mesothelioma, and other underserved cancers. In July 2015, Castle Biosciences closed the first tranche of a $20 million Series F financing round, raising $11.7 million. The round was led by Industry Ventures, with continued participation from existing investors including HealthQuest Capital and Mountain Group Partners. The funding was designated to accelerate clinical adoption of the company's DecisionDx-Melanoma test for cutaneous melanoma and advance its portfolio of other cancer diagnostic tools. Castle had achieved commercial traction with its uveal melanoma test and was scaling its cutaneous melanoma diagnostic into standard-of-care oncology workflows. The company expanded its sales and marketing infrastructure and secured payer contracts with MultiPlan, FedMed, and Preferred Medical Claim Solutions to make its tests available to more than 120 million covered lives. By appointing Veracyte CEO Bonnie Anderson to its board of directors in June 2015, Castle further strengthened its governance with diagnostics industry expertise. The company successfully continued its trajectory, completing its NASDAQ IPO (ticker CSTL) in July 2019 and subsequently expanding through acquisitions and organic growth, eventually exceeding $220 million in annual revenue by 2024.
Aug-14Series AHealthQuest Capital; Longfellow Venture Partners; Mountain Group Capital$12M—Castle Biosciences, a cancer-focused molecular diagnostics company based in Friendswood, Texas, completed an $11.8 million financing round on August 13, 2014. The round was led by new investor HealthQuest Capital, with participation from existing investors including Mountain Group Capital and Affiliates, Longfellow Venture Partners, and others. Garheng Kong, M.D., Ph.D., Managing Partner of HealthQuest Capital, joined the company's Board of Directors in conjunction with the financing. The funding supported the expansion of clinical availability for Castle Biosciences' portfolio of genomics-based tests targeting orphan and underserved cancers, including cutaneous melanoma, uveal melanoma, esophageal cancer, thymic cancers, mesothelioma, and gliomas. These tests help determine effective clinical approaches and potentially prevent unnecessary procedures. The company aimed to enhance clinical support, particularly for its novel gene expression profile assay identifying metastatic risk in cutaneous melanoma patients.
Nov-13Seed—$2M——
May-13Seed—$2M——

Castle Biosciences M&A Activity

Castle Biosciences has acquired 4 companies to date.

Last acquisition by Castle Biosciences was on May 5th 2025. Castle Biosciences acquired Previse for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Castle Biosciences

Previse
AltheaDx
Cernostics
MyPath Melanoma
Description
Previse is a Baltimore-headquartered biotechnology firm founded in 2020, concentrating on diagnostics, medical devices, therapeutics, and MedTech for early disease detection. The company develops AI-enhanced platforms for precision medicine, targeting cardiovascular and oncology applications with clinical validation studies underway in U.S. hospitals.
AltheaDx is a molecular diagnostics company offering PCR-based assays and biomarker services for oncology and infectious diseases. Its lab processes samples for gene expression, genotyping, and NGS panels supporting clinical trials. Located in San Diego, AltheaDx provides CLIA-certified testing for pharmaceutical partners evaluating companion diagnostics.
Cernostics is a life sciences company developing molecular diagnostic tests for cancer using its TissueCypher platform. Pittsburgh-headquartered, the technology analyzes whole-slide images with multiplexed immunofluorescence to assess tumor microenvironments in esophageal and gastric cancers. Cernostics partners with pharma companies for companion diagnostics supporting immunotherapy decisions.
MyPath Melanoma is a Salt Lake City-based CLIA-certified laboratory service from Castle Biosciences offering gene expression profiling for indeterminate melanocytic lesions. The assay distinguishes invasive melanoma from nevi using 23-gene signature, aiding dermatopathologists in risk stratification. Deployed since 2017, it supports treatment decisions in early-stage diagnostics.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
Baltimore, MD
San Diego, CA
San Francisco, CA
Salt Lake City, UT
Deal Date5 May 20254 Apr 202219 Oct 202127 Apr 2021
Valuationundisclosed$65M$3B$33M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Castle Biosciences acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Castle Biosciences

When was Castle Biosciences founded?Castle Biosciences was founded in 2007.
Where is Castle Biosciences headquartered?Castle Biosciences is headquartered in United States.
How many employees does Castle Biosciences have?As of today, Castle Biosciences has over 761 employees.
Who is the CEO of Castle Biosciences?Castle Biosciences' CEO is Derek J. Maetzold.
Is Castle Biosciences publicly listed?Yes, Castle Biosciences is a public company listed on Nasdaq.
What is the stock symbol of Castle Biosciences?Castle Biosciences trades under CSTL ticker.
When did Castle Biosciences go public?Castle Biosciences went public in 2019.
Who are competitors of Castle Biosciences?Castle Biosciences main competitors include Lumibird, Assure Tech, Integral Diagnostics, Jiangsu Bioperfectus, RaySearch Labs, Abclon, Genfit, Fulgent Genetics, Diagnósticos da América, Mirxes Holding.
What is the current market cap of Castle Biosciences?Castle Biosciences' current market cap is $624M.
What is the current revenue of Castle Biosciences?Castle Biosciences' last 12 months revenue is $347M.
What is the current revenue growth of Castle Biosciences?Castle Biosciences revenue growth (NTM/LTM) is 6%.
What is the current EV/Revenue multiple of Castle Biosciences?Current revenue multiple of Castle Biosciences is 1.1x.
Is Castle Biosciences profitable?Yes, Castle Biosciences is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Castle Biosciences?Castle Biosciences' last 12 months EBITDA is $28M.
What is Castle Biosciences' EBITDA margin?Castle Biosciences' last 12 months EBITDA margin is 8%.
What is the current EV/EBITDA multiple of Castle Biosciences?Current EBITDA multiple of Castle Biosciences is 14.4x.
What is the current FCF of Castle Biosciences?Castle Biosciences' last 12 months FCF is $6M.
What is Castle Biosciences' FCF margin?Castle Biosciences' last 12 months FCF margin is 2%.
What is the current EV/FCF multiple of Castle Biosciences?Current FCF multiple of Castle Biosciences is 61.9x.
How many companies Castle Biosciences has acquired to date?As of May 2026, Castle Biosciences has acquired 4 companies.
What was the largest acquisition by Castle Biosciences?$3B acquisition of Cernostics on 19th October 2021 was the largest M&A Castle Biosciences has done to date.
What companies Castle Biosciences acquired?Castle Biosciences acquired Cernostics, AltheaDx, MyPath Melanoma, and Previse.
In how many companies Castle Biosciences has invested to date?Castle Biosciences hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Castle Biosciences

Lists including Castle Biosciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial